-
Mashup Score: 2
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023; AUSTEDO ® – exceeding $1.6 billion in revenues, surpassing 2024 outlook; AJOVY ® – global annual revenues of $507 million, an increase of 18% in local currency terms compared to 2023; UZEDY ® revenues of $117 million in 2024 surpassing $100M outlook; Generics business continues to grow across all segments, with increases of 15% in the U.S., 6% in Europe and 15% in International Markets, all in local currency terms compared to 2023; First-to-market launches including first generic version of Sandostatin ® LAR Depot and liraglutide injection 1.8mg (an authorized generic of Victoza ® ); On January 2025, Teva entered into a license and supply agreement, for a proposed generic GLP1 in the U.S., Europe and additional countries; Biosimilar pipeline is expanding, and now includes 18 assets, including SELARSDI TM , which is expected to launch in the U.S. in the first quarter of 2025; and our
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2
Richard Francis, Teva Pharmaceuticals CEO, joins ‘Money Movers’ to discuss the company’s quarterly earnings results, drug price negotiations, and much more.
Source: www.cnbc.comCategories: General Medicine News, PayerTweet-
Teva CEO Richard Francis spoke with @moneymoverscnbc about our Q4 and full year 2024 performance, marking our second year of consecutive growth. Watch the full interview here: https://t.co/hrIFOem22r Forward-looking statements are subject to the cautionary note included in our… https://t.co/VZAoUNQ7VN https://t.co/kSlJ8rges5
-
-
Mashup Score: 2
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023; AUSTEDO ® – exceeding $1.6 billion in revenues, surpassing 2024 outlook; AJOVY ® – global annual revenues of $507 million, an increase of 18% in local currency terms compared to 2023; UZEDY ® revenues of $117 million in 2024 surpassing $100M outlook; Generics business continues to grow across all segments, with increases of 15% in the U.S., 6% in Europe and 15% in International Markets, all in local currency terms compared to 2023; First-to-market launches including first generic version of Sandostatin ® LAR Depot and liraglutide injection 1.8mg (an authorized generic of Victoza ® ); On January 2025, Teva entered into a license and supply agreement, for a proposed generic GLP1 in the U.S., Europe and additional countries; Biosimilar pipeline is expanding, and now includes 18 assets, including SELARSDI TM , which is expected to launch in the U.S. in the first quarter of 2025; and our
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q4 and FY 2024 business results. https://t.co/AtmmTiDSLj Forward-looking statements are subject to the cautionary note included in our Q4 2024 press release. #QuarterlyResults #Earnings… https://t.co/W86eQWC9fq https://t.co/Rl5UMraqAf
-
-
Mashup Score: 2Teva CEO on Drug Pricing, Generics, Supply Shortages - 17 day(s) ago
Teva Pharmaceuticals CEO Richard Francis reflects on company performance in 2024, drug pricing, getting more drugs to market and supply shortages of the drug Adderall. He speaks to “Bloomberg Open Interest” from the JPMorgan Healthcare Conference. (Source: Bloomberg)
Source: www.bloomberg.comCategories: General Medicine News, PayerTweet-
Speaking with Bloomberg at the J.P. Morgan Healthcare Conference 2025, Teva President and CEO Richard Francis reflected on the company’s exceptional performance in the first three quarters of 2024. Watch the full interview here: https://t.co/K9xVd1AhWe #TevaUSA #JPM25 https://t.co/pSd2vHaxAE
-
-
Mashup Score: 16Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease - 1 month(s) ago
Teva hosting investor call today at 8:00 a.m. ET (U.S.) Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibody Sanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions PARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva
Source: www.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS: Teva and @Sanofi announce positive topline results for our anti-TL1A program for patients with #IBD. Read more here: https://t.co/dqvjiFygIS $Teva https://t.co/RJwVLFBca5
-
-
Mashup Score: 5
For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023. AUSTEDO ® – shows continued growth, U.S. revenues of $435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming 2024 revenue outlook of ~$1.6 billion. AJOVY ® – global revenues of $137 million in Q3 2024, an increase of 21% in local currency terms compared to Q3 2023. UZEDY ® is gaining momentum – U.S. revenues of $35 million in Q3 2024; raising 2024 revenues outlook from ~$80 million to ~$100 million. Early and late-stage innovative pipeline continues to progress, with duvakitug (Anti-TL1A) top-line results expected in Q4 2024, and TEV-‘749 (olanzapine LAI) achieving phase III target injections without PDSS. Generics business grows across all regions – increased by 30% in the U.S., 8% in Europe and 13% in International Markets, in local currency terms compared
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q3 2024 business results. https://t.co/P8rEXLxooh Forward-looking statements are subject to the cautionary note included in our Q3 2024 press release. #QuarterlyResults #Earnings $Teva https://t.co/kdh7MEPSBd
-
-
Mashup Score: 4
For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023. AUSTEDO ® – shows continued growth, U.S. revenues of $435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming 2024 revenue outlook of ~$1.6 billion. AJOVY ® – global revenues of $137 million in Q3 2024, an increase of 21% in local currency terms compared to Q3 2023. UZEDY ® is gaining momentum – U.S. revenues of $35 million in Q3 2024; raising 2024 revenues outlook from ~$80 million to ~$100 million. Early and late-stage innovative pipeline continues to progress, with duvakitug (Anti-TL1A) top-line results expected in Q4 2024, and TEV-‘749 (olanzapine LAI) achieving phase III target injections without PDSS. Generics business grows across all regions – increased by 30% in the U.S., 8% in Europe and 13% in International Markets, in local currency terms compared
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q3 2024 business results. https://t.co/P8rEXLxooh Forward-looking statements are subject to the cautionary note included in our Q3 2024 press release. #QuarterlyResults #Earnings $Teva https://t.co/kdh7MEPSBd
-
-
Mashup Score: 7Expanding access to mental health care - 3 month(s) ago
Community Routes: Access to Mental Health Care — a partnership between Teva, Direct Relief and the National Association of Free and Charitable Clinics (NAFC) — is a unique access program that is helping to advance health equity and quality care for underserved populations across the U.S. Teva is providing commonly used medicines that treat depression and anxiety over $17 million as well as $2 million in grant funding over two years to support innovative behavioral health services through local free and
Source: www.tevausa.comCategories: General Medicine News, PayerTweet-
Big news! Teva, in partnership with @NAFClinics and @DirectRelief, is a winner of the @USCCFoundation Citizens Award. Read more about how our program is helping bring medicines to patients wherever they are. https://t.co/9otAJaNlzg #BusinessSolves #TevaUSA
-
-
Mashup Score: 4
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in April 2024 SELARSDI’s U.S. launch for all indications is expected in Q1 2025 REYKJAVIK, Iceland PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) – Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. This approval paves the way for SELARSDI to further align its label with the indications of the reference product Stelara ® (ustekinumab) in the U.S. at launch, which is expected
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS: The U.S. FDA approves an expanded label for one of our partnered #biosimilar products, extending to use in treatment of adults with Crohn’s disease and ulcerative colitis. Read more here: https://t.co/N60EM1e59S https://t.co/jvBgpFXDVQ
-
-
Mashup Score: 4Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA - 4 month(s) ago
Prolia ® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal women TVB-009P, Teva’s proposed biosimilar to Prolia, showed Phase 3 clinical results in osteoporosis and is part of Teva’s robust biosimilar portfolio – 7 approved biosimilars and 16 in the pipeline – across critical therapeutic areas such as oncology, immunology and respiratory medicine Anticipated decision by both agencies is expected in 2H 2025 TEL AVIV, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia ® (denosumab). 1 Both applications, a Biologics License Application (BLA) in the U.S., seeking interchangeability, and a Marketing Authorization Application (MAA) in the
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS: The U.S. Food and Drug Administration has accepted and the European Medicines Agency has validated applications for one of our biosimilar candidates. Read more here: https://t.co/Hjq82Ytm6Y https://t.co/6Und85woRS
-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q4 and FY 2024 business results. https://t.co/AtmmTiDSLj Forward-looking statements are subject to the cautionary note included in our Q4 2024 press release. #QuarterlyResults #Earnings… https://t.co/W86eQWC9fq https://t.co/Rl5UMraqAf